Benzinga | Jul 16, 2020 04:40PM EDT

Kodiak Sciences To Host R&D Webcast To Review Recent Data From Ongoing Phase 1b Study Of KSI-301 And Highlight KSI-301 Clinical Development Progress

PALO ALTO, Calif., July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D Webcast for investors and analysts on Monday, July 27 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

At the R&D webcast, Kodiak senior management will discuss recent safety, efficacy, and durability data from the ongoing Phase 1b study of KSI-301 in wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Management will also highlight continuing progress with the pivotal study of KSI-301 in treatment-na?ve wet AMD patients (DAZZLE) and review planned pivotal studies in DME, RVO and non-proliferative diabetic retinopathy (NPDR).

A live webcast of will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the event.

Investors, equity research analysts and others interested in participating in the Q&A portion of the event may contact ir@kodiak.com.